Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has provided an update.
On January 16, 2026, Tiziana Life Sciences priced a best-efforts registered direct offering of 6.4 million ordinary shares at $1.25 per share, raising expected gross proceeds of $8 million from senior management and existing shareholders, alongside one warrant per share that could bring in up to an additional $9.6 million if fully exercised before their July 16, 2026 expiry. The deal, which is expected to close on January 16, 2026, was heavily backed by insiders, including CEO Ivor Elrifi and Executive Chairman and founder Gabriele Cerrone, and is intended to fund completion of the company’s Phase 2 na-SPMS and MSA clinical trials through to top-line readouts, potentially strengthening Tiziana’s clinical and strategic position in neuroinflammatory therapies if the data are positive.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies using novel drug delivery technologies, particularly intranasal administration. Its lead asset is intranasal foralumab, a fully human anti-CD3 monoclonal antibody positioned as a potential treatment for neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA), supported by a growing patent estate for alternative routes of immunotherapy.
Average Trading Volume: 285,454
Technical Sentiment Signal: Hold
Current Market Cap: $174.7M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.